Analysts Set Expectations for VERV Q1 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV) – Stock analysts at William Blair issued their Q1 2026 earnings estimates for shares of Verve Therapeutics in a note issued to investors on Thursday, February 27th. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($0.77) for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share. William Blair also issued estimates for Verve Therapeutics’ Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.75) EPS and Q4 2026 earnings at ($0.77) EPS.

A number of other research analysts have also commented on VERV. HC Wainwright lifted their price objective on shares of Verve Therapeutics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Canaccord Genuity Group lifted their target price on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada lowered their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $25.50.

Verve Therapeutics Stock Performance

NASDAQ VERV opened at $6.12 on Monday. The firm has a market cap of $518.14 million, a PE ratio of -2.49 and a beta of 1.74. Verve Therapeutics has a one year low of $4.30 and a one year high of $16.05. The firm’s fifty day moving average is $6.92 and its two-hundred day moving average is $6.04.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.14. The firm had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%.

Institutional Trading of Verve Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Verve Therapeutics by 189.7% during the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock worth $34,000 after buying an additional 3,964 shares in the last quarter. IFP Advisors Inc boosted its holdings in Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after buying an additional 8,237 shares in the last quarter. Creative Planning purchased a new stake in Verve Therapeutics during the third quarter worth about $50,000. BNP Paribas Financial Markets purchased a new stake in Verve Therapeutics during the fourth quarter worth about $50,000. Finally, Erste Asset Management GmbH purchased a new stake in Verve Therapeutics during the third quarter worth about $56,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.